Everest Organics Peer Comparison

BSE: 524790

₹293.05

₹-2.80 (-0.95%)

As on 27-Aug-2026IST

Market cap

₹292 Cr

Revenue (TTM)

₹191 Cr

P/E Ratio

55.6

P/B Ratio

3.6

Div. Yield

0 %

Edit

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Market cap (₹ Cr)	292	21,703	19,323	17,803	18,177
Revenue (₹ Cr)	191	2,570	2,287	2,432	3,230
Net Profit (₹ Cr)	5.26	735.15	678.07	169.62	666.92
Net Margin (%)	2.74	26.88	28.10	6.90	20.60
RoE (%)	7.10	19.16	19.73	20.76	18.75
Price to Earnings	55.62	29.52	29.04	104.96	28.23
Price-To-Book	3.63	4.92	5.13	19.69	4.49

Income Statement (₹ Cr)

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Operating Revenue	190.78	2,569.77	2,287.33	2,432.06	3,229.67
Total Income	191.89	2,735.39	2,413.29	2,458.54	3,237.12
Total Expenditure	171.07	1,628.14	1,490.75	2,202.20	2,090.06
EBITDA	19.70	941.63	796.58	229.86	1,139.61
Depreciation	6.56	57.58	78.10	17.24	281.06
EBIT	13.15	884.05	718.48	212.62	858.55
Interest	6.85	7.69	0.88	5.72	190.64
Other Income	1.12	165.62	125.96	26.48	7.45
Exceptional Items	0.00	-49.16	0.00	-5.13	-17.24
Profit before Tax	7.41	992.82	843.56	228.25	658.12
Provision for Tax	2.16	257.67	165.49	58.63	-8.80
Profit after Tax	5.26	735.15	678.07	169.62	666.92

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Shareholder's Funds	75.48	4,202.90	3,586.42	872.79	3,902.67
Minority Interest	0.00	0.00	-12.71	0.00	-21.81
Non-Current Liabilities	12.13	91.50	28.74	134.50	1,392.75
Current Liabilities	152.20	627.48	385.94	981.81	2,077.10
Total Liabilities	224.48	4,911.11	3,207.85	1,879.19	6,862.28

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Non-Current Assets	68.38	770.28	1,291.22	42.47	5,617.77
Current Assets	167.43	3,803.22	2,585.66	1,739.93	1,539.85
Total Assets	224.48	4,911.11	3,207.85	1,879.19	6,862.28
Total Debt*	47.87	2.50	0.55	0.00	2,421.66
Net Current Assets	15.23	3,175.74	2,199.72	758.12	-537.25
Contingent Liabilities	5.54	363.79	0.64	98.41	64.29

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Cash From Operating Activities	-5.38	659.75	432.37	65.36	1,065.01
Cash Flow from Investing Activities	-5.17	-71.34	-334.73	30.80	-79.97
Cash from Financing Activities	16.36	-205.34	-38.32	-65.59	-881.32
Net Cash Inflow / Outflow	5.82	383.07	59.32	30.57	103.72

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
ROCE (%)	1.76	26.21	26.22	21.29	13.59
ROE (%)	7.10	19.16	19.73	20.76	18.75
ROA (%)	2.26	14.95	18.69	9.67	9.26
EBIT Margin (%)	6.89	34.40	31.41	8.74	26.58
Net Margin (%)	2.74	26.88	28.10	6.90	20.60
Cash Profit Margin (%)	0.00	0.00	0.00	0.00	0.00

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Revenue Growth (%)	5.49	10.69	15.01	31.10	9.59
EBIT Growth (%)	41.22	24.14	18.45	-12.99	16.84
Net Profit Growth (%)	-15.23	-9.09	19.61	-7.49	62.68
EPS Growth (%)	-20.40	14.40	17.73	-18.33	67.41
Book Value Growth (%)	50.41	17.30	23.77	7.70	10.19

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Price / Earnings	54.15	28.13	29.04	102.59	27.55
Price / Book Value	3.63	4.92	5.13	19.69	4.49
Dividend Yield (%)	0.00	1.58	0.16	0.51	0.55
EV/EBITDA	16.93	19.75	23.13	75.50	17.88
Market Cap (₹ Cr)	244.70	18,318.10	15,219.80	21,515.93	19,292.77

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debt to Equity	0.10	0.00	0.00	0.00	0.24
Short term debt to equity ratio	0.48	0.00	0.00	--	0.14
Current Ratio	1.10	6.06	6.70	1.77	0.74
Quick Ratio	0.81	5.31	5.59	0.73	0.53
Interest Coverage	2.08	130.11	959.59	40.90	4.45

	Everest Organics	Pfizer	Caplin Point Lab	Astrazeneca Pharma	Eris Lifesciences
Debtors to sales (%)	60.89	7.07	36.10	8.79	21.07
Asset Turnover	0.82	0.52	0.63	1.39	0.45
Receivable days	188.66	29.10	110.70	35.81	54.07
Inventory Days	89.08	69.53	65.86	82.25	32.16
Payable days	382.32	76.77	105.88	124.39	140.91
Cash Conversion Cycle	-104.59	21.86	70.68	-6.33	-54.68

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.